Optimal Duration Of Trastuzumab Therapy For Women With HER2+ Early Breast Cancer: New
New studies that advance understanding of the optimal duration of therapy with the targeted cancer drug trastuzumab were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna...